Haemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in March

Haemonetics Co. (NYSE:HAE) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 2,040,000 shares, a drop of 6.4% from the March 15th total of 2,180,000 shares. Based on an average daily trading volume, of 455,600 shares, the short-interest ratio is presently 4.5 days. Approximately 4.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HAE. Barrington Research reissued an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

Haemonetics Stock Down 0.8 %

Haemonetics stock traded down $0.71 during trading on Tuesday, reaching $84.17. 273,091 shares of the company’s stock were exchanged, compared to its average volume of 444,185. Haemonetics has a 52-week low of $70.74 and a 52-week high of $95.26. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The firm has a market cap of $4.27 billion, a price-to-earnings ratio of 34.39, a PEG ratio of 2.01 and a beta of 0.36. The company’s 50-day moving average is $78.42 and its two-hundred day moving average is $82.80.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.85 EPS. On average, analysts predict that Haemonetics will post 3.95 earnings per share for the current year.

Institutional Investors Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Haemonetics by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after acquiring an additional 27,146 shares during the period. Kingdon Capital Management L.L.C. bought a new position in Haemonetics in the 3rd quarter worth about $9,952,000. Lazard Asset Management LLC grew its position in Haemonetics by 114.2% in the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock worth $3,452,000 after purchasing an additional 20,550 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Haemonetics by 1.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock worth $4,753,000 after purchasing an additional 586 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in Haemonetics by 2.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock worth $24,065,000 after purchasing an additional 6,828 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.